Search details
1.
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.
N Engl J Med
; 390(2): 132-142, 2024 Jan 11.
Article
in English
| MEDLINE | ID: mdl-38197816
2.
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
N Engl J Med
; 390(20): 1849-1861, 2024 May 30.
Article
in English
| MEDLINE | ID: mdl-38739079
3.
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.
N Engl J Med
; 389(3): 239-250, 2023 Jul 20.
Article
in English
| MEDLINE | ID: mdl-37212440
4.
Intermediate-effect size p.Arg637Gln in FHOD3 increases risk of HCM and is associated with an aggressive phenotype in homozygous carriers.
J Med Genet
; 61(5): 423-427, 2024 Apr 19.
Article
in English
| MEDLINE | ID: mdl-38160043
5.
Alcoholic cardiomyopathy: an update.
Eur Heart J
; 2024 Jun 07.
Article
in English
| MEDLINE | ID: mdl-38848133
6.
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS).
J Card Fail
; 2024 Jun 21.
Article
in English
| MEDLINE | ID: mdl-38909877
7.
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
J Card Fail
; 2024 Mar 15.
Article
in English
| MEDLINE | ID: mdl-38493832
8.
Feasibility and safety of left bundle branch area pacing in cardiac amyloidosis. A single center experience.
Pacing Clin Electrophysiol
; 47(1): 149-155, 2024 01.
Article
in English
| MEDLINE | ID: mdl-38055612
9.
Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure.
Eur Heart J
; 44(48): 5064-5073, 2023 Dec 21.
Article
in English
| MEDLINE | ID: mdl-37639473
10.
Genetic Architecture of Acute Myocarditis and the Overlap With Inherited Cardiomyopathy.
Circulation
; 146(15): 1123-1134, 2022 10 11.
Article
in English
| MEDLINE | ID: mdl-36154167
11.
The SRSF4-GAS5-Glucocorticoid Receptor Axis Regulates Ventricular Hypertrophy.
Circ Res
; 129(6): 669-683, 2021 09 03.
Article
in English
| MEDLINE | ID: mdl-34333993
12.
OPHTHALMOLOGIC INVOLVEMENT IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS.
Retina
; 43(1): 49-56, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-36228151
13.
Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator.
Eur Heart J
; 43(32): 3053-3067, 2022 08 21.
Article
in English
| MEDLINE | ID: mdl-35766183
14.
Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy.
J Biol Chem
; 297(1): 100854, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34097875
15.
Non-invasive assessment of HFpEF in mouse models: current gaps and future directions.
BMC Med
; 20(1): 349, 2022 10 14.
Article
in English
| MEDLINE | ID: mdl-36229816
16.
Cardiac Transplantation in Danon Disease.
J Card Fail
; 28(4): 664-669, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34775111
17.
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.
Eur Heart J
; 42(16): 1554-1568, 2021 04 21.
Article
in English
| MEDLINE | ID: mdl-33825853
18.
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences.
Eur Heart J
; 42(2): 162-174, 2021 01 07.
Article
in English
| MEDLINE | ID: mdl-33156912
19.
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy.
Eur Heart J
; 42(32): 3063-3073, 2021 08 21.
Article
in English
| MEDLINE | ID: mdl-34263907
20.
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 396(10253): 759-769, 2020 09 12.
Article
in English
| MEDLINE | ID: mdl-32871100